| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Over the last 12 months, insiders at Prime Medicine, Inc. have bought $0 and sold $0 worth of Prime Medicine, Inc. stock.
On average, over the past 5 years, insiders at Prime Medicine, Inc. have bought $43.13M and sold $20.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,030,300 shares for transaction amount of $10M was made by NELSEN ROBERT () on 2025‑08‑01.
| 2025-08-01 | NELSEN ROBERT | 3.03M 1.988% | $3.30 | $10M | -9.03% | |||
| 2025-08-01 | ARCH Venture Partners XII, LLC | 10 percent owner | 3.03M 1.988% | $3.30 | $10M | -9.03% | ||
| 2025-08-01 | ARCH Venture Partners X, LLC | 10 percent owner | 3.03M 1.988% | $3.30 | $10M | -9.03% | ||
| 2025-08-01 | GV 2021 GP, L.L.C. | 10 percent owner | 1.5M 0.9841% | $3.30 | $4.95M | -9.03% | ||
| 2025-06-30 | Liu David R. | 10 percent owner | 21,000 0.0163% | $2.52 | $52,830 | +50.61% | ||
| 2025-06-23 | Liu David R. | 10 percent owner | 21,000 0.016% | $2.16 | $45,402 | +71.76% | ||
| 2025-06-16 | Liu David R. | 10 percent owner | 21,000 0.0158% | $1.49 | $31,196 | +147.33% | ||
| 2025-06-11 | Liu David R. | 10 percent owner | 21,000 0.0167% | $1.60 | $33,590 | +142.48% | ||
| 2025-05-21 | Reine Allan | Chief Executive Officer | 125,000 0.0962% | $1.18 | $147,150 | +217.09% | ||
| 2025-05-21 | LEE ANN L. | Chief Technical Officer | 100,000 0.0739% | $1.13 | $113,000 | +217.09% | ||
| 2025-05-20 | Brudnick Richard | Chief Business Officer | 20,000 0.0154% | $1.19 | $23,790 | +214.41% | ||
| 2024-02-15 | NELSEN ROBERT | 3.2M 4.6348% | $6.25 | $20M | -43.72% | |||
| 2024-02-15 | ARCH Venture Partners XII, LLC | 10 percent owner | 3.2M 4.6348% | $6.25 | $20M | -43.72% | ||
| 2024-02-15 | ARCH Venture Partners X, LLC | 10 percent owner | 3.2M 4.6348% | $6.25 | $20M | -43.72% | ||
| 2023-06-21 | Sale | GV 2019 GP, L.L.C. | 10 percent owner | 19,003 0.0659% | $14.97 | $284,496 | -48.21% | |
| 2023-06-20 | Sale | GV 2019 GP, L.L.C. | 10 percent owner | 37,405 0.1305% | $15.06 | $563,248 | -48.52% | |
| 2023-06-16 | Sale | GV 2019 GP, L.L.C. | 10 percent owner | 6,532 0.0227% | $15.02 | $98,109 | -46.91% | |
| 2023-06-15 | Sale | GV 2019 GP, L.L.C. | 10 percent owner | 66,659 0.2304% | $14.92 | $994,326 | -47.17% | |
| 2023-06-14 | Sale | GV 2019 GP, L.L.C. | 10 percent owner | 28,960 0.0998% | $14.87 | $430,684 | -46.33% | |
| 2023-06-13 | Sale | GV 2019 GP, L.L.C. | 10 percent owner | 28,100 0.0985% | $15.13 | $425,102 | -45.81% |
| Liu David R. | 10 percent owner | 20240945 11.2065% | $74.89M | 4 | 0 | +103.05% |
| NELSEN ROBERT | 6230300 3.4494% | $23.05M | 3 | 0 | <0.0001% | |
| ARCH Venture Partners X, LLC | 10 percent owner | 6230300 3.4494% | $23.05M | 3 | 0 | <0.0001% |
| ARCH Venture Partners XII, LLC | 10 percent owner | 6230300 3.4494% | $23.05M | 2 | 0 | <0.0001% |
| Cahill Thomas | director | 5305679 2.9375% | $19.63M | 1 | 0 | <0.0001% |
| GV 2021 GP, L.L.C. | 10 percent owner | 3262440 1.8063% | $12.07M | 1 | 0 | <0.0001% |
| Reine Allan | Chief Executive Officer | 125000 0.0692% | $462,500.00 | 1 | 0 | +217.09% |
| LEE ANN L. | Chief Technical Officer | 100000 0.0554% | $370,000.00 | 1 | 0 | +217.09% |
| Brudnick Richard | Chief Business Officer | 20000 0.0111% | $74,000.00 | 1 | 0 | +214.41% |
| GV 2019 GP, L.L.C. | 10 percent owner | 0 0% | $0 | 1 | 30 | <0.0001% |
$3,611,891 | 113 | 13.40% | $661.35M | |
$9,654,532 | 101 | -5.65% | $649.88M | |
$5,911,307 | 70 | -1.38% | $720.56M | |
$11,663,618 | 57 | 32.07% | $689.14M | |
$24,384,691 | 42 | -30.27% | $665.1M | |
$16,169,789 | 40 | 7.44% | $775.57M | |
$1,334,066 | 36 | 6.17% | $756.73M | |
$8,866,498 | 28 | 33.64% | $666.13M | |
$50,191,994 | 27 | 106.80% | $768.56M | |
$22,020,194 | 25 | 38.25% | $725.31M | |
Prime Medicine, Inc. (PRME) | $129,396,927 | 18 | 48.82% | $668.28M |
$133,809,976 | 13 | 31.29% | $605.85M | |
$6,385,840 | 12 | 0.69% | $627.73M | |
$57,263,116 | 11 | -8.37% | $679.96M | |
$130,748,265 | 10 | 53.98% | $613.63M | |
$75,069,528 | 10 | 19.77% | $675.87M | |
$272,024 | 7 | 16.80% | $733.03M | |
$2,720,023 | 3 | -11.76% | $609.97M | |
$7,234,370 | 3 | -3.34% | $637.73M |
| Increased Positions | 107 | +63.31% | 26M | +34.47% |
| Decreased Positions | 68 | -40.24% | 20M | -26.02% |
| New Positions | 43 | New | 5M | New |
| Sold Out Positions | 28 | Sold Out | 7M | Sold Out |
| Total Postitions | 208 | +23.08% | 82M | +8.46% |
| T. Rowe Price Investment Management, Inc. | $32,536.00 | 5.09% | 9.22M | +3M | +42.13% | 2025-09-30 |
| Blackrock, Inc. | $19,948.00 | 3.12% | 5.65M | +1M | +25.97% | 2025-09-30 |
| Ark Investment Management Llc | $19,337.00 | 3.03% | 5.48M | +3M | +135.84% | 2025-09-30 |
| Vanguard Group Inc | $17,374.00 | 2.72% | 4.92M | +1M | +35.68% | 2025-09-30 |
| Farallon Capital Management Llc | $16,768.00 | 2.62% | 4.75M | +4M | +533.33% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $12,814.00 | 2.01% | 3.63M | +2M | +127.65% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $12,814.00 | 2.01% | 3.63M | +2M | +128.42% | 2025-09-30 |
| Casdin Capital, Llc | $11,180.00 | 1.75% | 3.17M | +2M | +102.09% | 2025-09-30 |
| Woodline Partners Lp | $10,599.00 | 1.66% | 3M | +3M | New | 2025-09-30 |
| Ra Capital Management, L.P. | $10,590.00 | 1.66% | 3M | +3M | New | 2025-09-30 |